Sign inJoin waitlistJoin the waitlist

David O'Malley

Director, Division of Gynecologic Oncology · Ohio State University Hospital

Credentials: · · · ·

History

Ohio State University Hospital
Present

Gynecologic Oncology
Yale Univ Sch of Med
2003–2006
Case Western Reserve University
1999–2003
Wayne State University School of Medicine
1994–1998

Research

Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
The Lancet · 2017 · 1,408 citations
Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial
The Lancet Oncology · 2017 · 969 citations
Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network · 2021 · 587 citations

David Cohn
93 papers
Floor Backes
82 papers · 24 as a resident
Larry Copeland
78 papers
Jeffrey Fowler
47 papers
Bradley Monk
46 papers
Kathleen Moore
46 papers · 3 as a resident
RC
Robert Coleman
46 papers
Casey Cosgrove
38 papers · 20 as a resident
Ritu Salani
38 papers · 1 as a fellow
Christa Nagel
30 papers · 4 as a resident
Kristin Bixel
26 papers · 2 as a fellow
CA
Carol Aghajanian
24 papers

Grants

OSU as a Network Lead Academic Participating Site for the NCI NCTN
National Cancer Institute · UG1
PI · $7.8M · Ohio State University
2019–2026

Clinical trials

Biomarkers for Gynecologic Cancer
Principal investigator · Unknown
Ajinomoto Co., Inc.
2014–2018
Study of Intraperitoneal Carboplatin With IV Paclitaxel and Bevacizumab in Untreated Ovarian Cancer
Principal investigator · Completed · Phase 1
David O'Malley
2011–2023
Evaluation of Carboplatin/Paclitaxel/Bevacizumab in the Treatment of Advanced Stage Endometrial Carcinoma
Principal investigator · Completed · Phase 2
David O'Malley
2007–2017
A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.
Site PI · Recruiting · Phase 1
Whitehawk Therapeutics, Inc.
2026–2028